Department of Orthopedics and Traumatology, Beijing Jishuitan Hospital, Peking University Fourth School of Clinical Medicine, Beijing 100035, China.
Department of Anesthesiology, Beijing Jishuitan Hospital, Peking University Fourth School of Clinical Medicine, Beijing 100035, China.
Chin Med J (Engl). 2021 Jul 14;134(14):1720-1725. doi: 10.1097/CM9.0000000000001668.
Geriatric hip fracture patients receiving clopidogrel are a surgical challenge. In China, most of these patients undergo delayed surgical treatment after clopidogrel withdrawal for at least 5 to 7 days. However, delayed surgery is associated with increased complications and mortality in the older adults. This retrospective paralleled comparison study investigated the safety of early surgery for geriatric hip fracture patients within 5 days of clopidogrel withdrawal.
Acute hip fracture patients (≥65 years) who were hospitalized in the orthogeriatric co-management ward of Beijing Jishuitan Hospital between November 2016 and April 2018 were retrospectively reviewed. Sixty patients taking clopidogrel before injury and discontinued <5 days before surgery constituted the clopidogrel group. The control group constituted 60 patients not taking antiplatelet or anticoagulant drugs and matched 1:1 with the clopidogrel group for sex, fracture type, operative procedure, and time from injury to operation (±10 h). The primary outcome was perioperative blood loss and the secondary outcomes were transfusion requirement, complications, and mortality. The Student's t test or Wilcoxon signed rank sum test was used for continuous variables and the Chi-square test was used for categorical variables.
Age, body mass index, American Society of Anesthesiologists score, and percentage undergoing general anesthesia were comparable between the groups (P > 0.050). The percentages of patients with coronary heart disease (61.7% vs. 18.3%; P < 0.001) and cerebrovascular disease (45.0% vs. 15.0%; P < 0.010) were significantly higher in the clopidogrel vs. control groups, respectively. The median clopidogrel discontinuation time before operation was 73.0 (range: 3.0-120.0) h. There was no significant difference in the estimated perioperative blood loss between the clopidogrel group (median: 745 mL) and control group (median: 772 mL) (P = 0.866). The intra-operative transfusion rate was higher in the clopidogrel group (22/60, 36.7%) than that in the control group (12/60, 20.0%) (P < 0.050). However, there was no significant difference in the blood transfusion rate during the entire perioperative period (26/60, 43.3% vs. 20/60, 33.3%; clopidogrel group vs. control group, respectively; P > 0.050). There was no significant difference in perioperative complications, and 30-day and 1-year mortality rates between the groups.
Early hip fracture surgery is safe for elderly patients within 5 days of clopidogrel withdrawal, without increased perioperative blood loss, transfusion requirement, complications, and mortality compared with patients not taking antiplatelet drugs.
接受氯吡格雷治疗的老年髋部骨折患者是手术治疗的挑战。在中国,这些患者中的大多数在停用氯吡格雷至少 5 至 7 天后接受延迟手术治疗。然而,延迟手术与老年人并发症和死亡率的增加有关。这项回顾性平行对照研究调查了在停用氯吡格雷后 5 天内对老年髋部骨折患者进行早期手术的安全性。
回顾性分析 2016 年 11 月至 2018 年 4 月期间在北京积水潭医院骨科老年共管病房住院的急性髋部骨折患者(≥65 岁)。60 例受伤前服用氯吡格雷且停药<5 天的患者构成氯吡格雷组。对照组由 60 例未服用抗血小板或抗凝药物的患者组成,按性别、骨折类型、手术方式和从受伤到手术的时间(±10 小时)与氯吡格雷组 1:1 匹配。主要结局是围手术期出血量,次要结局是输血需求、并发症和死亡率。连续变量采用学生 t 检验或 Wilcoxon 符号秩和检验,分类变量采用卡方检验。
两组患者的年龄、体重指数、美国麻醉师协会评分和全身麻醉百分比相当(P>0.050)。氯吡格雷组的冠心病(61.7% vs. 18.3%;P<0.001)和脑血管病(45.0% vs. 15.0%;P<0.010)患者比例明显高于对照组。两组患者氯吡格雷停药时间中位数分别为 73.0(范围:3.0-120.0)小时和 772.0 毫升(P=0.866)。氯吡格雷组(中位数:745.0 毫升)与对照组(中位数:772.0 毫升)的围手术期估计出血量无显著差异(P=0.866)。氯吡格雷组术中输血率(22/60,36.7%)高于对照组(12/60,20.0%)(P<0.050)。然而,整个围手术期的输血率无显著差异(26/60,43.3% vs. 20/60,33.3%;氯吡格雷组 vs. 对照组;P>0.050)。两组患者围手术期并发症发生率和 30 天及 1 年死亡率无显著差异。
对于停用氯吡格雷后 5 天内的老年患者,早期髋部骨折手术是安全的,与未服用抗血小板药物的患者相比,围手术期出血量、输血需求、并发症和死亡率无显著增加。